Arqule Inc (ARQL)

1.00
0.00 0.03
NASDAQ : Health Care
Prev Close 1.00
Open 0.99
Day Low/High 0.95 / 1.04
52 Wk Low/High 1.37 / 2.65
Volume 35.85K
Avg Volume 216.40K
Exchange NASDAQ
Shares Outstanding 71.15M
Market Cap 71.86M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ArQule To Present At The 16th Annual Needham Healthcare Conference On April 4, 2017

ArQule To Present At The 16th Annual Needham Healthcare Conference On April 4, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

ArQule Announces Top-Line Results Of Phase 3 Clinical Study Of Tivantinib In Hepatocellular Carcinoma In Japan

ArQule Announces Top-Line Results Of Phase 3 Clinical Study Of Tivantinib In Hepatocellular Carcinoma In Japan

ArQule, Inc. (Nasdaq: ARQL) today reported that its partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint of...

ArQule Reports Fourth Quarter And Full Year 2016 Financial Results

ArQule Reports Fourth Quarter And Full Year 2016 Financial Results

ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2016.

ArQule To Report Fourth Quarter And Year End 2016 Financial Results On March 7, 2017

ArQule To Report Fourth Quarter And Year End 2016 Financial Results On March 7, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year 2016 before the market opens on Tuesday, March 7, 2017.

Daiichi Sankyo And ArQule Announce The Completion Of The METIV-HCC Phase 3 Study Of Tivantinib In Second-Line Treatment Of MET-Overexpressing Hepatocellular Carcinoma

Daiichi Sankyo And ArQule Announce The Completion Of The METIV-HCC Phase 3 Study Of Tivantinib In Second-Line Treatment Of MET-Overexpressing Hepatocellular Carcinoma

ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did not meet its primary endpoint of improving overall survival.

ArQule To Present At The Leerink Partners 6th Annual Global Healthcare Conference On February 15, 2017

ArQule To Present At The Leerink Partners 6th Annual Global Healthcare Conference On February 15, 2017

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

Data On Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition Of Wild Type And C481S Mutant BTK And Superiority To Ibrutinib In TCL1 Mouse Model Presented At The American Society Of Hematology Annual Meeting

Data On Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition Of Wild Type And C481S Mutant BTK And Superiority To Ibrutinib In TCL1 Mouse Model Presented At The American Society Of Hematology Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on Bruton's tyrosine kinase (BTK) inhibitor, ARQ 531, in a poster presentation by The Ohio State University at the American Society of...

Preclinical Data On Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness In The Treatment Of Sickle Cell Disease Presented At The American Society Of Hematology Annual Meeting

Preclinical Data On Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness In The Treatment Of Sickle Cell Disease Presented At The American Society Of Hematology Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data was presented on its proprietary AKT inhibitor, ARQ 092, in an oral presentation by the University of Illinois College of Medicine at the American Society of...

ArQule Reports Third Quarter 2016 Financial Results

ArQule Reports Third Quarter 2016 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2016.

Advancements In ArQule's Proprietary Pipeline To Be Highlighted At The 2016 American Society Of Hematology Annual Meeting

Advancements In ArQule's Proprietary Pipeline To Be Highlighted At The 2016 American Society Of Hematology Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data will be presented on two molecules from its proprietary pipeline at the 2016 American Society of Hematology (ASH) Annual Meeting in San Diego,...

ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016

ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2016 before the market opens on Monday, November 7, 2016.

ArQule To Present At The Leerink Partners Rare Disease And Immuno-Oncology Roundtable On September 28, 2016

ArQule To Present At The Leerink Partners Rare Disease And Immuno-Oncology Roundtable On September 28, 2016

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

ArQule Announces Publication Of Manuscript Highlighting Preclinical Activity Of FGFR Inhibitor, ARQ 087, In Peer Reviewed Journal

ArQule Announces Publication Of Manuscript Highlighting Preclinical Activity Of FGFR Inhibitor, ARQ 087, In Peer Reviewed Journal

ArQule, Inc. (Nasdaq: ARQL) today announced the publication of a paper detailing the preclinical profile of ARQ 087, an orally available fibroblast growth factor receptor (FGFR) inhibitor.

ArQule Reports Second Quarter 2016 Financial Results

ArQule Reports Second Quarter 2016 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2016.